MONALEESA-2: Compelling survival data with ribociclib a ‘step forward’ in HR+/HER2- ABC
Adding ribociclib (KISQALI, Novartis) to letrozole yields significant and consistent overall survival (OS) benefit compared with letrozole alone in the first-line setting for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), according to the final OS analysis of the MONALEESA-2 trial presented at ESMO 2021.
